Non Hodgkin Lymphoma Clinical Trial
Study of IMPT-314 in R/R Aggressive B-cell
This is a Phase 1/2, multi-center, open-label study evaluating the safety and efficacy of IMPT-314, a bispecific chimeric antigen receptor (CAR) targeting cluster of differentiation (CD)19 and CD20 in participants with aggressive B-cell NHL.
Up to 30 patients will be enrolled in dose finding Phase 1 part of the study, which will determine the recommended phase 2 dose.
Phase 2 will enroll 20 additional participants to evaluate further the safety and efficacy of IMPT-314.
IMPT-314 treatment consists of a single infusion of CAR-transduced autologous T cells administered intravenously after a conditioning chemotherapy regimen consisting of fludarabine and cyclophosphamide, administered over 3 days.
Individual participants will remain in the active post-treatment period for approximately 2 years. Participants will continue in long-term follow-up for 15 years from treatment.
Age 18 years or older
Willing and able to provide written informed consent
Histologically confirmed aggressive NHL, including the following types defined by the World Health Organization (WHO) 2017:
DLBCL not otherwise specified (NOS)
DLBCL arising from follicular lymphoma
Primary mediastinal (thymic) large B-cell lymphoma
High-grade large B-cell lymphoma with or without MYC and BCL2 and/or BCL6 rearrangement
Received at least 2 prior lines of therapy. Prior therapy must have included:
Anti-CD20 monoclonal antibody
An anthracycline containing chemotherapy regimen
Participants with TFL must have received at least one of their prior lines of therapy after transformation to DLBCL
Relapsed or refractory disease, defined by the following:
Disease progression after last regimen (including salvage therapy after autologous stem cell transplantation [ASCT]), or
Refractory disease is defined failure to achieve a PR or CR to the last regimen
At least 1 measurable lesion (the Lugano classification). Lesions that have been previously irradiated will be considered measurable only if progression has been documented following completion of radiation therapy
Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1
Absolute neutrophil count (ANC) ≥ 1000/uL
Other protocol-defined criteria apply.
History of malignancy other than non-melanoma skin cancer or carcinoma in situ (e.g., cervix, bladder, breast) unless disease-free for at least 3 years. Participants who have received therapy for a prior malignancy within the prior 3 years, e.g., in the adjuvant setting, are not excluded
Active central nervous system (CNS) involvement by malignancy on magnetic resonance imaging (MRI) or by lumbar puncture. Participants with prior evidence of brain metastasis successfully treated at least 8 weeks prior to enrollment will not be excluded for participation if they are deemed under control at the time of study enrollment
History of cardiac lymphoma involvement
Ongoing or impending oncologic emergency (e.g., tumor mass effect, tumor lysis syndrome)
Received the following therapies in the specified time frame prior to enrollment/leukapheresis
Any systemic therapy within 2 weeks
Any systemic inhibitory/stimulatory immune checkpoint molecule therapy within 3 half-lives prior to enrollment (e.g., ipilimumab, nivolumab, pembrolizumab, atezolizumab, OX40 agonists, 4-
Bendamustine or fludarabine within 12 weeks
Alemtuzumab or antithymocyte globuline (ATG) within 6 months
Received radiation therapy within 3 weeks prior to enrollment
Experiencing toxicities due to prior therapy (stable and recovered to grade ≤ 1 or non- clinically significant toxicities such as alopecia are allowed)
History of allogeneic stem cell transplantation
Receipt of autologous stem cell transplantation within 6 weeks prior to enrollment
History of prior genetically modified T cell therapy other than a product targeting CD19 with an FMC63-based CAR (e.g., axicabtagene ciloleucel (axi-cel, YESCARTA®), tisagenlecleucel (tisa-cel, KYMRIAH®), or lisocabtagene maraleucel (liso-cel, BREYANZI®)
History of autoimmune disease (e.g., Crohn's disease, rheumatoid arthritis, systemic lupus) resulting in end organ injury or requiring systemic immunosuppression/systemic disease modifying agents within the last 2 years
Other protocol-defined criteria apply.
Check Your Eligibility
Let’s see if you might be eligible for this study.
What is your age and gender ?
There are 5 Locations for this study
How clear is this clinincal trial information?
Introducing, the Journey Bar
Use this bar to access information about the steps in your cancer journey.